JPL Wealth Management LLC Acquires Shares of 30,461 GSK plc (NYSE:GSK)

JPL Wealth Management LLC purchased a new stake in shares of GSK plc (NYSE:GSK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,461 shares of the pharmaceutical company's stock, valued at approximately $1,129,000.

Several other institutional investors also recently bought and sold shares of the business. Horizon Bancorp Inc. IN grew its holdings in GSK by 8.9% in the fourth quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company's stock worth $147,000 after purchasing an additional 323 shares during the last quarter. Cerity Partners LLC lifted its position in GSK by 305.7% during the fourth quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company's stock valued at $4,383,000 after purchasing an additional 89,089 shares during the period. Avantax Advisory Services Inc. lifted its position in GSK by 23.6% during the third quarter. Avantax Advisory Services Inc. now owns 76,840 shares of the pharmaceutical company's stock valued at $2,785,000 after purchasing an additional 14,689 shares during the period. International Assets Investment Management LLC acquired a new position in GSK during the fourth quarter valued at $7,024,000. Finally, Kestra Private Wealth Services LLC lifted its position in GSK by 18.9% during the third quarter. Kestra Private Wealth Services LLC now owns 25,754 shares of the pharmaceutical company's stock valued at $934,000 after purchasing an additional 4,101 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Price Performance

GSK stock traded up $1.31 during midday trading on Wednesday, reaching $45.77. The company had a trading volume of 6,830,575 shares, compared to its average volume of 3,534,931. The company has a market capitalization of $94.86 billion, a P/E ratio of 16.58, a P/E/G ratio of 1.91 and a beta of 0.65. GSK plc has a 12-month low of $33.33 and a 12-month high of $45.92. The firm's fifty day simple moving average is $42.38 and its 200-day simple moving average is $39.98. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.15. The firm had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. As a group, equities analysts anticipate that GSK plc will post 4.1 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be issued a $0.3762 dividend. This is an increase from GSK's previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.29%. GSK's dividend payout ratio is presently 53.26%.

Analyst Ratings Changes

GSK has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an "equal weight" rating for the company. Citigroup raised shares of GSK from a "neutral" rating to a "buy" rating in a research note on Tuesday, February 13th. Finally, Guggenheim raised shares of GSK from a "neutral" rating to a "buy" rating in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy".

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.